

XBP1-US/XBP1-SP/CD138/CS1 Circular RNA for Cancer Vaccine Research

Catalog Number:CVAC-ORNA-0496

DESCRIPTION	
Product Name	XBP1-US/XBP1-SP/CD138/CS1 Circular RNA for Cancer Vaccine Research
Gene Name	XBP1-US/XBP1-SP/CD138/CS1
Source	In vitro transcribed mRNA was further circularized to make this product as a circular RNA.
Alternative names	XBP1-US/XBP1-SP/CD138/CS1 Multipeptide Vaccine PVX-410
SPECIFICATIONS	
Cap	
5'-UTR	5' -untranslated region derived from human alpha-globin RNA with an optimized Kozak sequence
ORF	XBP1-US/XBP1-SP/CD138/CS1
3'-UTR	3' UTR comprising two sequence elements derived from the aminoterminal enhancer of split (AES) mRNA and the mitochondrial encoded 12S ribosomal RNA
Poly(A) Tail	
Modifications	N1-methyl-pseudouridine
Neutral Lipid	1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC)
Cholesterol	Cholesterol
Lonizable Lipid	1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (PEG2000-DMG)
PEG-lipid	Heptadecan-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate)(SM-102)
Storage	-80 °C
Buffer	PBS, pH7.5
Cryoprotectant	Trehalose
BACKGROUND	
Gene Accession	
Gene Alias	XBP1-US/XBP1-SP/CD138/CS1 Multipeptide Vaccine PVX-410

stimulate the immune system to induce a cytotoxic T-lymphocyte response against the four myeloma-specific antigens. The tumor associated antigens (TAAs) XBP1-US, XBP1-SP, CD138 and CS1, are overexpressed on the surface of multiple myeloma (MM) cells. (NCIT_C103823).

Background

Description: A cancer vaccine containing immunogenic, HLA-A2-specific epitopes derived from X-box-binding protein 1-unspliced (XBP1-US), XBP1-spliced (SP), syndecan-1 (CD138), and CS1 (CD2 subset 1, CRACC, SLAMF7, CD319) with potential immunomodulating and antineoplastic activities. Upon subcutaneous administration, XBP1-US/XBP1-SP/CD138/CS1 multi-peptide vaccine PVX-410 may